Expert Opinion on Drug Safety, 1474-0338

Journal

Related Publications
  1. Stakeholders' perspectives on a patient-reported outcome measure-based drug safety monitoring system for immune-mediated inflammatory diseases

    Kosse, L. J., Jessurun, N. T., Vonkeman, H. E., Tas, S. W., Nurmohamed, M. T., Hoentjen, F., van Doorn, M. B. A., van Puijenbroek, E. P., van den Bemt, B. J. F. & de Vries, M., 30-Jul-2020, In : Expert Opinion on Drug Safety.

    Research output: Contribution to journalArticleAcademicpeer-review

  2. Immune-mediated inflammatory disease patients' preferences in adverse drug reaction information regarding biologics

    Kosse, L. J., Weits, G., Vonkeman, H. E., Spuls, P. I., Van Den Bemt, B. J. F., Tas, S. W., Hoentjen, F., Nurmohamed, M. T., Van Doorn, M. B. A., Van Puijenbroek, E. P. & Jessurun, N. T., 7-Jul-2020, In : Expert Opinion on Drug Safety. p. 1-5 5 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  3. Safety profile of non-vitamin K oral anticoagulants (NOACs) from a patient perspective: A web-based cohort event monitoring study

    Rolfes, L., Ekhart, C., Hendriks, J., van der Horst, P. & van Puijenbroek, E., 2019, In : Expert Opinion on Drug Safety. 18, 9, p. 869-874 6 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  4. First experiences with a tool to measure the level of clinical information present in adverse drug reaction reports

    Oosterhuis, I., Rolfes, L., Ekhart, C., Muller-Hansma, A. & Harmark, L., 2018, In : Expert Opinion on Drug Safety. 17, 2, p. 111-115 5 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  5. An update on the safety of psychostimulants for the treatment of attention-deficit/hyperactivity disorder

    Groenman, A. P., Schweren, L. J. S., Dietrich, A. & Hoekstra, P. J., Apr-2017, In : Expert Opinion on Drug Safety. 16, 4, p. 455-464 10 p.

    Research output: Contribution to journalReview articleAcademicpeer-review

View all (16) »

ID: 2387572